Hereditary Angioedema Prophylaxis
BCRXBioCryst Pharmaceuticals Inc.Catalyst overview
Research summary
This catalyst tracks a Phase 3 data readout for Navenibart (Plasma Kallikrein Inhibitor) in Hereditary Angioedema Prophylaxis. The expected timing is based on the latest available company guidance and may change.
08/05/26:- ALPHA-ORBIT enrollment completed; top-line navenibart data expected in Q3 2027.
Verification
Confirm timing and program details against the company announcement or filing.